Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	664.67	1,582	29,507	45,435	15,383	36,775
Short-Term Investments	-	-	-	-0	-	-
Cash & Short-Term Investments	664.67	1,582	29,507	45,435	15,383	36,775
Cash Growth	-93.43%	-94.64%	-35.06%	195.36%	-58.17%	766.97%
Accounts Receivable	193.02	438.43	389.19	1,074	40.75	1,175
Other Receivables	1,273	4,525	1,265	999.61	2,036	7,077
Receivables	1,466	4,963	1,654	2,073	2,077	8,252
Inventory	29,749	26,909	17,805	6,833	12,034	9,697
Prepaid Expenses	121.91	224.64	222.48	147.86	129.05	62.23
Other Current Assets	2,551	7,170	6,446	15,754	213.14	73.2
Total Current Assets	34,553	40,848	55,636	70,242	29,835	54,860
Property, Plant & Equipment	232,131	228,406	233,052	234,435	227,107	149,989
Other Intangible Assets	1,520	1,032	676.96	1,047	1,108	1,791
Other Long-Term Assets	-	0	50	28.82	28.82	128.82
Total Assets	268,204	270,286	289,414	305,753	258,079	206,768

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6,853	7,237	3,048	587.44	1,011	3,328
Accrued Expenses	509.17	504.58	6,636	3,149	1,612	841.4
Short-Term Debt	47,498	44,627	36,726	30,209	-	-
Current Portion of Long-Term Debt	13,067	14,156	10,824	12,914	10,604	6,434
Current Portion of Leases	28.57	12.17	66.17	39.68	98.57	134.63
Current Unearned Revenue	263.16	263.16	573.03	578.25	1,247	1,100
Other Current Liabilities	67,847	35,617	34,432	41,620	17,978	16,555
Total Current Liabilities	136,067	102,417	92,306	89,098	32,552	28,393
Long-Term Debt	24,500	32,666	125,414	116,846	107,900	71,428
Long-Term Leases	-	-	12.17	6.72	16.68	115.25
Other Long-Term Liabilities	-	-	-	-	0	-0
Total Liabilities	160,566	135,083	217,732	205,950	140,468	99,936

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	38,876	38,876	30,751	30,554	30,554	23,603
Additional Paid-In Capital	341,501	341,501	257,963	256,059	256,059	202,489
Retained Earnings	-281,769	-245,907	-218,437	-189,063	-171,084	-121,366
Comprehensive Income & Other	9,030	732.73	1,406	2,253	2,082	2,105
Shareholders' Equity	107,638	135,203	71,682	99,803	117,611	106,832
Total Liabilities & Equity	268,204	270,286	289,414	305,753	258,079	206,768

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	85,093	91,461	173,043	160,016	118,619	78,112
Net Cash (Debt)	-84,428	-89,879	-143,536	-114,581	-103,236	-41,337
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-978.82	-1218.84	-2345.53	-1953.28	-1994.89	-930.05
Filing Date Shares Outstanding	77.75	77.75	61.5	61.11	61.11	47.21
Total Common Shares Outstanding	77.75	77.75	61.5	61.11	61.11	47.21
Working Capital	-101,513	-61,568	-36,670	-18,855	-2,716	26,467
Book Value Per Share	1384.37	1738.89	1165.54	1633.22	1924.65	2263.08
Tangible Book Value	106,118	134,171	71,005	98,756	116,504	105,041
Tangible Book Value Per Share	1364.82	1725.61	1154.53	1616.08	1906.52	2225.15
Land	18,863	10,565	10,565	10,565	10,565	10,565
Buildings	70,181	70,180	70,180	70,150	68,072	37,381
Machinery	70,473	59,390	56,143	37,728	37,566	22,529
Construction In Progress	75,660	95,463	90,441	126,395	117,130	78,220

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error